szeged, sept. 28th 2007 1 inserm french national institute of health and medical research created in...

1Szeged, Sept. 28th 2007

InsermInsermFrench National Institute of Health

andMedical Research

•Created in 1964 from the National Institute of Hygiene and Hospital Research

•Working through the Ministries for Research and Health


Inserm : key figures

Budget 2007 : 700 M€Total staff: 13 000

(2 500 physicians) of which 4900 Inserm employees: 2100 scientists and 2800

technical staff (62% of total budget dedicated to salaries)

335 Inserm laboratories25 research centers

374 French and foreign firms are partners of Inserm

An active patent portfolio of 572 families

41 Clinical Investigation Centers (CIC)

56 start-up companies based on Inserm technology


What is Inserm ?

The French performing research organisation entirely dedicated to Biomedical & Clinical research and Public Health

All fields of research are covered in these domains

90% of the 335 research units are located in University hospitals Research units with 8 years mandate with mid-term (4 year)

evaluation. Stringent evaluation

Investigator- driven projects - AVENIR programme

Close collaboration with French Funding agencies (ANR, INCa ANRS), Sanitary agencies (InVS, AFSSAPS), Charities (AFM, …) and industrial partners.


The Inserm performance

about:blank


OrganizationOrganization Bottom-up initiatives: selection based on Bottom-up initiatives: selection based on

qualityquality and and innovationinnovation

Networks focused on major public health Networks focused on major public health issues: “National Research Programs”:issues: “National Research Programs”:- Diabetes, Cardiovascular, Hepato-Gastro- Diabetes, Cardiovascular, Hepato-Gastro-

EnterologyEnterology- Bone and joint diseases, endocrinology and Bone and joint diseases, endocrinology and

reproduction etc…. reproduction etc….


Bone and Joint Diseases

2.2%

Diabetes2.6%

Hepatitis 3.1%

Genetic diseases

10.5%

16.8%Cancer

Cardiovascular diseases

9.1%

17.1%Immunology

of which 9.3%for neurologic disorders

20.6%

Neurosciences

Infectious diseasesand microbiology

(without Aids and Hepatitis)

8.3%

Public health7.5%

Handicap5.1%

Nutrition4.8% AIDS

3.7%

Research laboratories being often involved in more than one domain, the overall distribution is over 100 %


Research organizations CNRS, CEA, Inra, Inria, IRD, Pasteur Institute,

Curie Institute

Scientific & medical societies, Patients

associations, Foundation, Charities

Universities Industry

Hospitals

National research & Public health

agencies

International scientific

community


Inserm : creation of research centers

Objectives and main characteristics:• Critical mass (100 to 300 staffs),• Mutualisation and Integration• International visibility, Attractiveness

Assessment criteria:• Scientific excellence• Quality of the management :

Governing structure, mutualised administration & managementTechnology transfert and research outcomes

Sharing of technical facitiliesCoordination of scientific events and programmesImplementation of research training programmesInternational scientific council for evaluation of scientific strategy (turn-over of scientific teams : mobility, hosting new scientists or teams,…)


25 Research Centers in 2007

Some exemples: 1- Paris 6, Pluri-thematic2- Paris 6, Neurophysiology4- Paris 5, Pluri-thematic5- Créteil, Pluri-thematic6- Lilles, Pluri-thematic7- Dijon, Cancer/Nutrition8- Bordeaux, Neurophysiology9- Grenoble, Neurophysiology10- Grenoble, Cancer11- Toulouse, Pluri-thematic


Inserm Unit 5967 departments

550 staffs Strasbourg

3 Avenir programs

Facilities- Cellular imaging- DNA microarray platform- Monoclonal Antibody- Structural biology- Bio-informatic- Protéomics

Thematics- Molecular pathology- Developmental and physiological gentics - Fonctional genomics- Cellular biologie and signal transduction- Molecular neurobiology

Partners- Inserm - Louis Pasteur University- CNRS

Technology transfer- > 20 contrats with industries- Public-private Partnerships

Director : D.Moras

www-igbmc.u-strasbg.fr


Facilities- Proteomics- Biotherapy- Cytometry - Cellular imaging - Animal imaging

Centre de recherche Jean-Pierre AubertJPARC

Director : Pierre Formstecher

Thematics- Neurosciences- Cellular différenciation and cancer

Partners- Lille 2 University- Lille University Hospital - Inserm

Inserm Unit 8375 teams

150 staffs Lille

Technology transfer- Public-private Partnerships

www.crjpa.lille.inserm.fr


Institut du Fer à MoulinIFM

Director : Jean-Antoine Girault

Facilities- Animals - Cellular imaging- Quantitative PCR- Cytometry- Peptide synthesis- Proteomics

Technology transfer- Public-private Partnerships

ThematicsSignalling mechanisms involved in the nervous system developpement

Partners- Université Paris 6- Paris University hospital- Inserm

Inserm Unit 83919 teams99 staffs

Paris1 Avenir program


Evolution of Research Units and Research centers at Inserm (from 2001 to 2007)


Research infrastructures

• National Genomic Research Consortium: CNRG National Sequencing Center National Genotyping Center Regional Genopoles Core Facilities • Biosafety-level 4 laboratory

• Local and regional technological plateforms

• Clinical Research Infrastructures


Functional exploratory platform/animals

National Biological resources :

11

13

Animal experimentations

Transcriptomics

Proteomics

Bioinformatic

in vivo imaging

Structural biology

Cellular imaging

Sequencing

Human biological resources

Electronic microscopy

Lipidomics

Vegetal experimentations

Chemistry

Bacterial

2

9

6

4

5

4

8

2

1

1

1

1

6

Lille

Rouen

Caen

Paris

Reims

Nancy

StrasbourgRennes

ToursOrléans

DijonNantes

Lyon

Bordeaux

GrenobleClermont-Ferrand

Poitiers

NiceToulouse

MarseilleMontpellier

1 1

2 1 1

1 1

1

2

1 11 1

1 1

1 1

1 1

1 1 1

1

1 1

1

1

1

1

1

6 4

1 4 1

1 1

1

1

1

1

1

Rousset

1

1 1

1 1

1

1

1

1

1

11

1

1

1

1

1

1

1

Research platforms


Main Inserm’s priorities

1. « Researchers » : Careers, Training & Mobility

2. To focus Inserm on its main mission: support both basic and clinical research; develop translational research with a multidisciplinary approach

3. To establish Inserm in a European and International context

4. To develop public/private partnerships


Researchers : Career, Training and Mobility


Career tracks at Inserm

• Junior, temporary contract (5 years with a 3-year intermediate evaluation), high level (research director) contracts

Avenir programEuropean programs: EURYI, ERC

• Permanent positions for senior scientists


AVENIR Programme

• Eligibility: Young scientists with permanent or temporary position, clinicians

• Aim: To strengthen the status of young scientists; to recognize, evaluate and continuously promote scientific qualities

• A yearly budget of 200K euros for 5 years

• Minimum lab space of 50 m2

• Running costs

• Salaries, human resources (Post-doc, engineers, technicians)


Interface contracts : General principles

• Based on :a permanent position + temporary, 3-5 year contracts

• To reinforce interactions with partners and mobility

- Hospitals: clinical research, medical issues- Health agencies: health policy issues- Universities: teaching, making scientific

information available to the society

• Industry: technological transfer and valorisation

• European partners / European mobility (a new scheme of the Marie Curie actions - PEOPLE programme ?)


Interface contracts for Inserm scientists :Tenure position + 3-5 year contracts: " 2/3 – 1/3 "

Tenuredscientists

Hospital

Internationalinstitutions

Sanitary Agencies

« Internal » Inserm

UniversityIndustry


Interface Contract grants for MDs

• Reinforce research activities of clinicians and university research assistants and professors

• 3-5 year contracts for clinicians : assistant professors and professors, university employees

• Grant paid by Inserm to hospitals and universities to be used for : - clinical and teaching activities: temporary positions - financing research activities


The School of InsermThe School of Inserm

A 3-year Theoretical and Practical Education which leads to a Master’s

• First year of Inserm School - Second year of Medical School :

Special School Intensive Training Session in February

June: Competitive Exam

• Second year of Inserm School - Third year of Medical School

6 month full time Research Clerkship in an Inserm Research Laboratory

• Third year of Inserm School - Interruption of Medical School : Clerkship in a Research Laboratory and educational program for the Master Degree


Clinical research and Translational research strategy


BasicResearch

Preclinical studies : Proof of concept

Inserm Inserm

[CRC]

Inserm

Phases IIb-III

Phase IVCohorts

Clinical trialsClinical trials

Proof of conceptPhases I-IIaBiotherapy


Inserm, as a major actor of the Clinical Research in France and in Europe

• To set-up an efficient Translational research towards the benefits of patients

• To develop dedicated performing Research Infrastructures : ECRIN, GMP facilities platforms (innovative biomedicines), BRCs, (Roadmap ESFRI)

• To sponsor clinical studies and innovative therapeutic clinical trials

• To ensure appropriate training of Physicians to Research skills and vice-versa : School of Inserm

• To built a continuum from Basic research to Clinical Research


Clinical research infrastructures

2006 2001 2002 2003 2004 2005

Clinical research centers 41 17 21 28 31 41

Tissues Banks 47 16 30 47 47 47

Cohorts 118 131 135 142 147 147

Registries 35 17 29 29 31 35

Networks 22 9 22 22 22 22


41 Clinical Investigation Centres

• CIC

• Epidemiology studies

• Biotherapy

Access to patientsSupport to investigators


FranceInserm

Spain SCReN

SwedenSweCRIN

GermanyKKS

DenmarkDCRIN

ItalyIRFMN & CIRM

HungaryHECRIN

UKUKCRN

Ireland ICRIN

EFGCP

National networks of Clinical Research Centres / Clinical Trial Units

AustriaATCRIN

SwitzerlandSCRN

EORTC

FinlandFinnCRIN

European Clinical Research Infrastructures Network, co-ordinated by INSERM:Pan-Europeaninfrastructure providing services to the preparation and the conduct of multinational clinical studies, with GMP facilities for biotherapy


Biological Resources Centres

a networking action at both National and European Levels


• Science Case: A European network to coordinate European Scientific programs

and policies Clinical data and follow-up of patients and Healthy volunteers Innovative targets, biomarkers, clinical studies Technology transfer, dissemination of knowledge, valorisation

• Technical case: Repositories for qualified biological samples (DNA, RNA, proteins,

…), coupled to clinical data. Providers/distributors of samples within scientific project objectives Development of QA standards for European BRCs To store samples for the future (heritage) Distributed facilities / centralised database

Network of Biological Resources Facilities Cohorts of Patients


The necessity of a European network :

To co-ordinate European scientific programs and policies : 7th PCRD

To develop and harmonize assurance-quality standards for European BRCs : exchanges of authenticated biological materials.

Valorisation of knowledge

Attractiveness of public research and development of innovative SMEs.

European Biological Resources network (BBMRI)


Platforms for GMP production

State of the art :

Platforms for production of therapeutic vectors : Nantes (Atlantic biothérapies), Généthon, etc.

Platforms for production of bio-medicines : LFB, Genopole Ile-de-France, Vivalis, Lipidomix, etc.

Platforms for production of therapeutic virus : Heidelberg

Perspectives : availability of GMP products

Partnership with Inserm-Transfert Costs sharing European dimension : ESFRI / IMI


EU approach for of GMP Facilities

• Needs : to develop innovative “non-commercial” clinical trials - Lack of specific financial support

• Science Case: Reinforcing clinical research and translation of basic research to

therapy Production and evaluation of innovative therapeutic and

diagnostic agents : biomarkers and biotherapy / regenerative medicine : cell therapy, gene therapy, tissue engineering

• Technical case: Production of new therapeutic/diagnostic agents from

biotechnologies Products for Cell and Gene therapy Good Manufacturing Practices (GMO dissemination regulation), in

line with national legislation, able to cooperate across the borders Direct links with Clinical Research Centres (CRC - ECRIN)


IMI : Innovative Medicines for Europe

European Joint Technology Initiative (JTI) to develop new therapeutic drugs in a faster and safer way.

Inserm is the French representative in the Member states contact Group of IMI


Competitivity Clusters

Atlantic Biothérapies

Cancer Bio Santé

Prod’Innov

Lyonbiopôle Virology

Innovations thérapeutiques

Nutrition Santé Longévité

Medicen

Orpheme

Nutrition

International

National

Emergent

Imaging, Cancer, Biotehrapy, Neurosciences

Cancer Bio SantéRéunion

Qualitropic

67 created clusters 7 involving Inserm units


The European policy of Inserm


Inserm’s priorities in Europe

1. « Researchers » : attractive careers, training, mobility

2. “European” Research Laboratories: European Associated Laboratories, Joint Unit abroad

3. Research Infrastructures for biomedical research (ECRIN, Biobanks, EATRIS) and Translational research based on Public-Private Partnership (IMI - European Joint Technology Initiative)

4. FP7 and other European programmes of interest

5. EU Prospectives (ESF-EMRC, EUROHORCS,etc.)=> Green paper on new perspectives of ERA


Multilateral cooperations’ actions

Inserm in FP6Inserm in FP6

• around 150 EU research projects• 224 participating research teams• 26 in coordination

Inserm in FP7Inserm in FP7

First call of the Health priority : Total of 152 selected projects, out of which7 coordinated by Inserm

(preliminary data)


Bilateral cooperations’ actions

Researchers' mobility (short-medium term, Interface Contract grants)

European research networks at the bilateral level and within the EU programmes

European Associated laboratories

Joint Research unit abroad


Bilateral cooperations’ tools:Associated Laboratories and Inserm’s Units abroad

Scientifically driven

8 years mandate with mid-term evaluation

Synergies: competencies and facility access

Co-funded by Inserm and Associated partner

Temporary/permanent positions (Mobility of Post-Doc, researchers - Interface contracts)

Institutional “label”

Leverage effect for additional funding


BrusselsHeidelberg

Glasgow

Rome

Milan

Prague

Dundee

Barcelona

Porto

European Associated Laboratories (LEA)

Toulouse : D. Langin U586 / Prague : V. Stich (Univ. Charles)

Lille : M. Capron U547 / Brussels : M. Goldman (IMI)

Toulouse : AC Prats U589 / Dundee : JC Bourdon (Univ. Dundee)

Bordeaux: A. Bikfalvi E 113 / Milan: L. Bello (Univ. Degli Stuli)

Nice: G. Meneguzzi U 634 / Rome: G. Zambruno (IDI-IRCCS)

Villejuif: D. Samuel U 785 / Rome: M. Levrero (Univ. La Sapienza)

Montpellier: K. Ritchie U 888 / London: G. Thornicroft (King’s College of London)

Strasbourg: T. Baumert U 748 / Freiburg: H. Blum (Univ. of Freiburg)

Villejuif: T. Moreau U 780/ Barcelona: J. Antό (PRBB, IMIM-CREAL)

Bordeaux: L. Bordenave U 577 / Porto: M. Barbosa (IBMC, INEB)

London

Freiburg

Joint Research Unit in Europe:

Université de Glasgow / C. Doerig

U609

DKFZ / J. Rommelaere U701


Montreal

Pittsburgh

Rio de Janeiro

INSERM UnitAssociated LaboratoryIn preparation

Irvine

Montreal

Shanghai

Tokyo

Kyoto

SeoulNew York

NanjingDallas

BeijingHaïfa

Doha

Los Angeles

Buenos Aires

Laval

WuhanRabat

Guangzhou

Singapour


International Cooperation Contracts (up to 4 years) Salary paid by “home” institution + additional salary

paid by “host” institution Reciprocal, bi-directional (Imperial College London,

CNR,…)=> Marie Curie « Co-fund » Programme (FP7)

Joint Post-doctoral training contracts

2 phases, commitment for a contractual recruitment when they return, bidirectional call for applications

Prospectives towards Internationalisation of School of Inserm

European Mobility of Researchers« Towards a European Career Track »


Joint post-doctoral career track

• 3-year post-doctoral positions in host institutions: Joint selection with Inserm

Joint calls under preparation with European

institutions (ICL, Univ. Dundee, Porto…)

• Evaluation at the end of post-doctoral fellowship

• Junior, 5-year Inserm contract

• Tenure: Inserm, CNRS, University, industry etc ..


Cooperations between Inserm and Cooperations between Inserm and Hungarian PartnersHungarian Partners

46

148 joint publications Inserm – Hungarian partners since 2000

Main Partner Institutions : Institutes of the Hungarian Academy of Sciences (BRC Szeged), Semmelweis University Budapest, University of Debrecen

Main thematic areas : Neurosciences, Cardiovascular diseases, Molecular and Cell Biology, Biochemistry etc.

6 Hungarian Researchers and Fellows within Inserm's research units in 2006

18 FP6 projects involving Inserm and Hungarian partners(6 NoEs - 10 IPs - 2 STREP)

Further FP7 collaborations (IMI, ECRIN, BRCs…)


TransfertTransfert

• Inserm’s private subsidiary• Created in 2001, funded up to € 4,5 million• 60 people with scientific/industrial background

Missions:• Drive value creation from Inserm research• Allow an efficient partnering with the Industry• Ensure a fair economic return towards Inserm• Contribute to economic development


Development of services covering the whole technology transfer process :

• Detection of inventions / “coaching”• Protection of inventions & follow up / intellectual property management• Pre-technology transfer / Applied and Translational Research• Technology Transfer, collaborative and R&D agreements• Preclinical Development / Proof of Concept development• Industrial Partnerships / Clinical trials development• International and European projects management• Biotech start up coaching and funding (pre seed fund Inserm Transfert Initiative)• Legal and financial expertise

Proximity between both scientific and industrial communitiesfor a best partnership development

Integrated Technology Transfer Skills“From the bench to the partnering and the license”

InsermResearch

Intellectual Property License

Biotech start-up

Detection of Inventions

TransfertTransfert


Contacts :Inserm’s web site : www.inserm.fr/en/inserm

Department of French Regional and European Strategic Policies

• Anne Bisagni, Director : [email protected]

• Philippe Arhets, Deputy Director : [email protected]

• Cécile Bergouignan, Bilateral cooperation :

[email protected]

Human Resources : Researchers task force

• Anne-Marie Laffaye, School of Inserm, Avenir :

[email protected]

• Richard Salives, Marie Curie Programme :

[email protected]

szeged, sept. 28th 2007 1 inserm french national institute of health and medical research created in...

Documents

medical research

research laboratories

research outcomes

hospital research

fields of research

health slide

national research programs

biomedical clinical